Загрузка...
Targeting Plk1 to enhance efficacy of Olaparib in castration-resistant prostate cancer
Olaparib is a FDA-approved PARP inhibitor (PARPi) that has shown promise as a synthetic lethal treatment approach for BRCA-mutant castration-resistant prostate cancer (CRPC) in clinical use. However, emerging data has also shown that even BRCA-mutant cells may be resistant to PARPi. The mechanistic...
Сохранить в:
| Опубликовано в: : | Mol Cancer Ther |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5337144/ https://ncbi.nlm.nih.gov/pubmed/28069876 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0361 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|